- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03891056
Metabolic Surgery; Gastric Bypass vs Sleeve Gastrectomy; Efects Over Type 2 DM With Bad Metabolic Control (MSO1CT) (MSO1CT)
METABOLIC SURGERY FOR PATIENTS WITH TYPE 2 DM AND GRADE I OBESITY (BMI 30-35 kg/m2) WITH BAD METABOLIC CONTROL (HbA1c > 7,5%) PROTOCOL
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Hyphotesis Laparoscopic gastric bypass is the elective technique in the face of sleeve gastrectomy to improve or heal type 2 diabetes mellitus in patientes with BMI 30-35 kg/m2.
MAIN AIM:
To compare cure rate through the improvement in glycated hemoglobin and fasting glycaemia after laparoscopic gastric bypass face to sleeve gastrectomy.
SECONDARY AIMS:
To quantify both insulin and oral hypoglycemic agents dose decrease. To measure weight loss and its maintenance during the follow-up in both techniques.
To compare postoperative complications. To compare postoperative pain. To compare follow-up complications.
Matherial and methods. Type of study: Randomized clinical trial double blind with two paralel groups.
RANDOMIZATION. Randomization will be a simple one with Epidat 4.1. A number sequence will be carried out and it will be kept in opaque closed envelopes. The envelope will be opened the operation day and the surgery technique will be decided randomly, according to the randomization sequence. The study will be blinded for patients, who will not know the surgery technique they will go on. Dieticians and Endocrinologists who will follow the patients up after the surgery neither will not know it, so differences in dietary recommendations will not appear with this masking.
Subjects of study The study will rely on patients with Diabetes Mellitus type 2 and grade I obesity with HbA1c higher than 7,5 % (BMI 30-35 kg/m2 and type 2 diabetes with bad glycemic control) detected in Endocrinology and Nutrition Department of Hospital Doctor Peset. Patients will go on bariatric surgery in General and Digestive Surgery Department of the same hospital. Patients who accomplish established inclusion criteria will be recruited until sample size is completed; a minimum 40 patients size is estimated (with a type I error of 5% and a power of 80%) and the will be randomized in two 20 people branches. Investigation will follow The World Medical Association and Declaration of Helsinki guidelines.
Definition of healing and improvement. Healing will be defined when HbA1c and fasting glycaemia levels are inside normal limits without needing oral hypoglycemic agents.
Improvement will be defined when decreasing medication doses for keeping normal fasting glycaemia and level of HbA1c under 6%.
Period of study:
The required one for fulfilling the sample. An inclusion of 40 patients in two years is expected.
Variable-gathering period The patient will be call for attending the external consultation of the Endocrinology and Nutrition Department of Hospital Doctor Peset. Each subject will carry out an initial study with nutritional status assesment, cardiovascular risk factors and comorbidities (hypertension, obstructive sleep apnea, dyslipidemia), as well as discarding secondary causes of obesity. In basal state, 2 days, 3, 6 and 12 months after the surgery, a blood test consisting of biochemical analysis, specific proteins, serum hormones, inmunological markers, full blood count and hemostasis will be made. The patient will carry out dietary intervention and follow-up in each phase of the process.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Nuria Peris Tomás, PhD
- Telefonnummer: 0034 617019132
- E-mail: nuriapt27@gmail.com
Undersøgelse Kontakt Backup
- Navn: Jose Angel Diez Ares, PhD
- Telefonnummer: 0034 619702452
- E-mail: jose_angel_diez_ares@hotmail.com
Studiesteder
-
-
-
Valencia, Spanien, 46017
- Rekruttering
- Department of General and Digestive Surgery of the Dr. Peset Hospital
-
Kontakt:
- Nuria Peris Tomás, PhD
- Telefonnummer: 0034 617019132
- E-mail: nuriapt27@gmail.com
-
Kontakt:
- Jose Angel Diez Ares, PhD
- Telefonnummer: 0034 619702452
- E-mail: jose_angel_diez_ares@hotmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Both sex patients aged between 18 and 65 years old
- Class I obesity (BMI 30-35 kg/m2) with bad metabolic control (DM-2 with HbA1c > 7,5%) and non-insulin anti-diabetic treatment failure (it is necessary >10 years of known diabetes evolution time, C-peptide≥ 1 ng/ml, no insulin treatment, at least two oral hypoglycemic agents treatment);
- Patients who accomplish the follow-up protocol designed by both Surgery and Endocrinology departments
- Informed consent signed
Exclusion Criteria:
- Patients who do not accomplish the previosly described inclusion criteria; Patient's refusal to take part in the study; Patients with symptomatology of gastroesophageal reflux disease or with upper gastrointestinal series compatible with this desease.
Previous bariatric surgery
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Gastric bypass
Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
|
The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
|
Aktiv komparator: Slevee gastrectomy
Twenty patients will be randomly assigned to perform a sleeve gastrectomy
|
The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of participans with normal glycosylated hemoglobin levels
Tidsramme: 1 year after surgery
|
Healing will be defined when HbA1c and fasting glycaemia levels are inside normal limits (Hb1Ac < 6%, FBG<100mg/dl) without needing oral hypoglycemic agents.
|
1 year after surgery
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of participants with partial remission or improvement of diabetes
Tidsramme: 1 year after surgery
|
Partial remission: Subdiabetic hyperglycemia (Hb1Ac 6%-6,4%, FBG 100-125mg/dl) in the absence anti diabetic medication. Improvement: statistically significant reduction in Hb1Ac and FBG not meeting criteria for remission or decrease in anti diabetic medication requirement (by one oral agent, or 1/2 reduction in dose) |
1 year after surgery
|
Comparison of weight loss between the two techniques; bypass and sleeve.
Tidsramme: 2 years after surgery
|
To measure weight loss and its maintenance during the follow-up in both techniques.
For this, the patients will be weighed in the postoperative period at month, 3, 6 12 months and then annually.
|
2 years after surgery
|
Evaluation of postoperative complications in patients undergoing bypass and slevee with Clavien-Dindo classification.
Tidsramme: 1 month after surgery
|
Grade I: any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions. Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgesics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. Grade II: Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusions and total parenteral nutritional also included. Grade III: Requiring surgical, endoscopic or radiological intervention. Grade IV: Life-threatening complication requiring IC/ICU management. Grade V: Death of a patient. |
1 month after surgery
|
Comparison postoperative pain in sleeve and bypass with analogue assessment scale of postoperative pain.
Tidsramme: 3 days postoperative
|
The postoperative pain of the patients during the first three postoperative days will be evaluated with the visual analogue scale from 0 (no pain) to 10 (unbearable pain).
|
3 days postoperative
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MSO1CT
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Diabetes mellitus
-
Medical College of WisconsinMedical University of South CarolinaAfsluttetDiabetes mellitus | Type 2 diabetes mellitus | Voksen-debuterende diabetes mellitus | Ikke-insulinafhængig diabetes mellitus | Ikke-insulinafhængig diabetes mellitus, type IIForenede Stater
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
SanofiAfsluttetType 1-diabetes mellitus-type 2-diabetes mellitusUngarn, Den Russiske Føderation, Tyskland, Polen, Japan, Forenede Stater, Finland
-
Meir Medical CenterAfsluttetDiabetes mellitus type 2 | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, om oral hypoglykæmisk behandling | Voksen type diabetes mellitusIsrael
-
Guang NingRekrutteringType 2 diabetes mellitus | Type 1 diabetes mellitus | Monogenetisk diabetes | Pancreatogen diabetes | Lægemiddel-induceret diabetes mellitus | Andre former for diabetes mellitusKina
-
Hoffmann-La RocheRoche DiagnosticsAfsluttetDiabetes mellitus type 2, diabetes mellitus type 1Tyskland
-
Peking Union Medical College HospitalUkendtType 2 diabetes mellitus | Type 1 diabetes mellitus | Svangerskabsdiabetes mellitus | Pancreatogen diabetes mellitus | Prægestationsdiabetes mellitus | Diabetespatienter i perioperativ periodeKina
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and...Aktiv, ikke rekrutterendeDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AfsluttetDiabetes mellitus, type 2 | Diabetes mellitus, type II | Diabetes mellitus, voksendebut | Diabetes mellitus, ikke-insulinafhængig | Diabetes mellitus, ikke-insulinafhængigForenede Stater
Kliniske forsøg med metabolic surgery
-
Myota GmbHLindus HealthAfsluttetPræ-diabetesDet Forenede Kongerige
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of Sheffield; Nutricia UK LtdAfsluttetRygmarvsskade, akutDet Forenede Kongerige
-
Arizona State UniversityAfsluttet
-
Royal Surrey County Hospital NHS Foundation TrustUkendtLivmoderhalskræft | Æggelederkræft | Peritoneal kræft | Neoplasma i æggestokkene | Ovarie neoplasma epitelialDet Forenede Kongerige
-
Grupo Español de Rehabilitación MultimodalInstituto de Salud Carlos III; Instituto de Investigación Sanitaria AragónRekrutteringStørre operationSpanien
-
University of Colorado, DenverRekrutteringForbedret restitution efter operation | Gynækologisk sygdomForenede Stater
-
The Second Hospital of Shandong UniversityRekrutteringLungekræft | Kirurgi | ERASKina
-
University Hospital, GrenobleAfsluttet
-
ARCAGY/ GINECO GROUPRekrutteringOvariekræft Stadium IIIC | Ovariekræft Stadium IV | Ovariekræft Stadium IIIbFrankrig
-
Bournemouth UniversityStryker Orthopaedics; Nuffield Health Bournemouth; Orthopaedic Research InstituteRekrutteringSlidgigt, HofteDet Forenede Kongerige